Bristol Myers Squibb said it will enroll more patients in a key Phase 3 trial studying its drug Cobenfy in psychosis associated with Alzheimer’s disease, after the company found “irregularities due to ...

Detailed price information for Centessa Pharmaceuticals Plc ADR (CNTA-Q) from The Globe and Mail including charting and trades.

ARLINGTON, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (Nasdaq:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of ...

HAYWARD, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Aarvik Therapeutics announces a global license and assignment Agreement with NJ Bio, Inc. to secure a class of novel proprietary payloads with a ...

What Happened? A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official ...

Processa Pharmaceuticals, Inc. announced its participation in the 2025 BIO International Convention from June 16-19 in Boston, where key executives, including CEO Georg Ng and President of R&D Dr.

BridgeBio jumps on major clinical wins, strong launches and rare-disease programs targeting large markets with new drugs ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most profitable biotech stocks to buy. Wells Fargo maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on October 21 and set ...

Shanghai Fudan Zhangjiang Bio Pharmaceutical Co ( ($HK:1349) ) just unveiled an update. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

ORLEANS, Ontario, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc (“Tetra” or the “Company”) (TSX VENTURE: TBP) (OTCQB: TBPMF), a leader in cannabinoid-based drug discovery and development has ...

Ironwood Pharma remains undervalued despite a failed $1bn Vectiv Bio acquisition and subsequent stock plunge, with Linzess ...

The Korea Pharmaceutical and Bio-Pharma Manufacturers Association held a board meeting on the 15th and announced the appointment of Lee Jae-guk as the next vice chairman and other full-time executives ...